Create issue ticket

1,266 Possible Causes for 1, FKBP12, and, ( ) Rapamycin, target

Did you mean: 1, FKBP12, and, ( ), Rapamycin, target

  • Sirolimus

    Intravitreal sirolimus resolves inflammation in noninfectious intermediate or posterior uveitis: SAKURA study 1. Presented at: American Academy of Ophthalmology meeting.[healio.com] Rapamycin (gold) is a small molecule with a high affinity for FKBP12. When it binds to FKBP12, it creates a composite surface which in turn binds to FRAP.[hhmi.org] Rapamycin (sirolimus) is a macrolide immunosuppressant that inhibits the mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in model organisms including[ncbi.nlm.nih.gov] Functions of the mammalian TOR protein The members of the Target of Rapamycin (TOR) subfamily are uniquely targeted for inhibition by rapamycin, a feature that has greatly[dx.doi.org] Clinical outcomes at 1 year for the intention-to-treat group were 12.2% TLF and 14.3% MACE and for the per-protocol population were 2.8% TLF and 2.8% MACE.[ncbi.nlm.nih.gov]

    Missing: and
  • Immunosuppressive Drug

    Review Topic QID: 101013 1 Nephrotoxicity, hypertension 3 Hyperlipidemia, thrombocytopenia 4 Cytokine release syndrome, hypersensitivity reaction 5 Nephrotoxicity, gingival[medbullets.com] FKBP12, known as FK506 binding protein, binds to immunosuppressive drug FK506, which must be taken by patients who received organ transplant.[ncbi.nlm.nih.gov] A c-jun antisense expression vector efficiently prevented rapamycin-induced MMP-1 gene transcription.[ncbi.nlm.nih.gov] To identify the target proteins responsible for FK506's neuroprotective effects, the drug affinity responsive target stability (DARTS) method was performed using label-free[ncbi.nlm.nih.gov] Abstract Several studies have demonstrated that endothelin-1 (ET-1) plays an important pathophysiological role in ischaemic renal failure and drug-induced renal injury, such[ncbi.nlm.nih.gov]

    Missing: and
  • Lymphangioleiomyomatosis

    Fig. 1.[doi.org] FKBP12–rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions . J. Biol. Chem. 275 , 7416–7423 (2000). 23.[doi.org] In addition, treatment of three primary IGF2-expressing LAM lung cell lines with rapamycin did not result in IGF2 level changes.[ncbi.nlm.nih.gov] Clinical trials using molecularly targeted agents such as endocrine manipulation and mammalian target of rapamycin (mTOR) inhibitors are in progress, but the status of these[ncbi.nlm.nih.gov] Upon entering the cell, rapamycin binds to FK506-binding protein of 12 kDa (FKBP12) and interacts with the FKBP12-rapamycin binding domain (FRB) of mTOR, thus inhibiting mTORC1[doi.org]

    Missing: and
  • Pulmonary Lymphangioleiomyomatosis

    Fig. 1.[doi.org] FKBP12–rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions . J. Biol. Chem. 275 , 7416–7423 (2000). 23.[doi.org] Based on experimental work that rapamycin may inhibit angiomyolipoma cells, we commenced the patient on low-dose rapamycin.[ncbi.nlm.nih.gov] However, methodical and targeted approaches toward understanding LAM pathophysiology have led to the discovery of new potential therapeutic avenues.[ncbi.nlm.nih.gov] Upon entering the cell, rapamycin binds to FK506-binding protein of 12 kDa (FKBP12) and interacts with the FKBP12-rapamycin binding domain (FRB) of mTOR, thus inhibiting mTORC1[doi.org]

    Missing: and
  • Renal Cell Carcinoma

    Priolo C 1 , Khabibullin D 2 , Reznik E 3, 4 , Filippakis H 2 , Ogórek B 2 , Kavanagh TR 2 , Nijmeh J 2 , Herbert ZT 5 , Asara JM 6 , Kwiatkowski DJ 2 , Wu CL 7 , Henske EP[ncbi.nlm.nih.gov] The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12).[cancer.gov] Targeted drugs, including inhibitors of the vascular endothelial growth factor and mammalian target of rapamycin pathways, have shown robust effectiveness and offer new therapeutic[ncbi.nlm.nih.gov] Targeting the vascular endothelial growth factor and its receptor, or the mammalian target of rapamycin complex, remains the foundation of systemic treatment.[ncbi.nlm.nih.gov] […] mRCC whose disease progresses during initial VEGFr-TKI therapy may continue treatment with a different VEGFr-TKI or they may switch to treatment with a mammalian target of rapamycin[ncbi.nlm.nih.gov]

    Missing: and
  • Tuberous Sclerosis

    S1 - 1st & 2nd Medical Students S2 - 3rd & 4th Medical Students L1 - PGY1 & PGY2 L2 - PGY3 L3 - PGY4 L4 - PGY5 L5 - Fellow L6 - 1-3 years in practice L7 - 3-10 years in practice[medbullets.com] Mammalian target of rapamycin inhibitors (mTORI) are increasingly used in the treatment of tuberous sclerosis complex (TSC) and as immunosuppressants after organ transplantation[ncbi.nlm.nih.gov] Patient history, prenatal fetal echocardiography, and targeted genomic sequencing may facilitate screening for, diagnosis of, and counseling for TSC.[ncbi.nlm.nih.gov] Of 7 patients with CC (58%) who were following the maintenance protocol, 6 relapsed within 7 months and 1 was still responding at 1 year.[ncbi.nlm.nih.gov] Abdominal imaging of 15 patients with tuberous sclerosis complex-associated renal cystic disease who had received mammalian target of rapamycin inhibitor therapy for other[ncbi.nlm.nih.gov]

    Missing: FKBP12 and
  • Tuberous Sclerosis Type 2

    Abstract A 700-kb region of DNA in human chromosome 16p13.3 has been shown to contain the polycystic kidney disease 1 (PKD1) and the tuberous sclerosis type 2 (TSC2) disease[ncbi.nlm.nih.gov] Furthermore, mammalian target of rapamycin complex 1 inhibitors like everolimus and sirolimus may be administered. They constitute a causal therapy.[symptoma.com] In its entirety, it is called the hamartin-tuberin complex and suppresses the activity of mammalian target of rapamycin complex 1.[symptoma.com] The overall incidence of tuberous sclerosis has been estimated to 1-2 in 10,000 life births.[symptoma.com] Pharmacotherapy with everolimus, sirolimus, or related compounds is also indicated in case of angiomylipomas or lymphangioleiomyomatosis, and frequently contributes to the[symptoma.com]

    Missing: FKBP12 and
  • Tuberous Sclerosis Type 1

    The overall incidence of tuberous sclerosis has been estimated to 1-2 in 10,000 life births.[symptoma.com] Furthermore, mammalian target of rapamycin complex 1 inhibitors like everolimus and sirolimus may be administered. They constitute a causal therapy.[symptoma.com] In its entirety, it is called the hamartin-tuberin complex and suppresses the activity of mammalian target of rapamycin complex 1.[symptoma.com] Adult-onset angiofibromas may, by contrast, suggest Birt-Hogg-Dubé syndrome or multiple endocrine neoplasia type 1.[symptoma.com] Pharmacotherapy with everolimus, sirolimus, or related compounds is also indicated in case of angiomylipomas or lymphangioleiomyomatosis, and frequently contributes to the[symptoma.com]

    Missing: FKBP12 and
  • Subependymal Giant Cell Astrocytoma

    MIB-1 immunostaining was also performed in all of the cases, and MIB-1 indices (the percentage of MIB-1-positive nuclei) ranged from 0.1 to 3.8 (mean, 1.1).[ncbi.nlm.nih.gov] Mammalian target of rapamycin inhibition involves complex signaling pathways inducing subependymal giant cell astrocytoma shrinkage.[ncbi.nlm.nih.gov] In such patients, the mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to induce responses.[ncbi.nlm.nih.gov] Neurocytomas were positive for TTF-1 in 4/19 (21%) of cases using clone 8G7G3/1 and in 9/19 (47%) of cases using clone SPT24.[ncbi.nlm.nih.gov] Magnetic resonance imaging of the brain 2(1/2) months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5[ncbi.nlm.nih.gov]

    Missing: FKBP12 and
  • Tacrolimus

    Analyses were performed on 3 periods: 1 month, 1 month to 1 year, and after 1 year post-transplantation.[ncbi.nlm.nih.gov] This FKBP12-FK506 complex interacts with and inhibits calcineurin thus inhibiting both T-lymphotye signal transduction and IL-2 transcription.[agscientific.com] The aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA) on the release of three local factors directly implicated in[ncbi.nlm.nih.gov] Nano-delivery systems have gained remarkable recognition for targeted delivery of therapeutic payload, reduced off-target effects, and improved biopharmaceutical profiles[ncbi.nlm.nih.gov] The following trough range is a suggested guideline: 5.0-20.0 mcg/L Sirolimus Trough: 3.0-18.0 mcg/L Clinical Significance Tacrolimus (FK506) and Sirolimus (Rapamycin) are[questdiagnostics.com]

    Missing: and